公开(公告)号：US20240156750A1

公开(公告)日：2024-05-16

申请号：US18336440

申请日：2023-06-16

申请人： Mitochon Pharmaceuticals, Inc.

发明人： Robert ALONSO ,  John GEISLER

IPC分类号： A61K31/06 ,  A61K9/00

CPC分类号： A61K31/06 ,  A61K9/0019 ,  A61K9/0053

摘要： A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. DNP was administered to mice daily over a range of doses, and subsequently BDNF expression in the brain showed a dose dependent and non-linear increase in expression.

公开(公告)号：US20210052513A1

公开(公告)日：2021-02-25

申请号：US17093193

申请日：2020-11-09

申请人： Mitochon Pharmaceuticals, Inc.

发明人： Robert ALONSO ,  John Gerard GEISLER

IPC分类号： A61K31/06 ,  A61K9/00

摘要： A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. DNP was administered to mice daily over a range of doses, and subsequently BDNF expression in the brain showed a dose dependent and non-linear increase in expression.

公开(公告)号：US20170065536A1

公开(公告)日：2017-03-09

申请号：US15357412

申请日：2016-11-21

申请人： Mitochon Pharmaceuticals, Inc.

发明人： Robert ALONSO ,  John Gerard GEISLER

IPC分类号： A61K31/06

CPC分类号： A61K31/06 ,  A61K9/0019 ,  A61K9/0053

摘要： A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. DNP was administered to mice daily over a range of doses, and subsequently BDNF expression in the brain showed a dose dependent and non-linear increase in expression.

摘要翻译： 一种治疗与衰老相关的神经肌肉，神经退行性，发育性，自身免疫性和代谢性疾病/紊乱的诸如创伤性损伤，中风，亨廷顿病，癫痫，多发性硬化（MS），狼疮，1型和2型 糖尿病，成熟期青少年糖尿病（MODY），重症肌无力（MG），类风湿性关节炎（RA），格雷夫斯病，吉兰巴利综合征（GBS），代谢综合征，肌营养不良或杜氏肌营养不良（DMD），严重 烧伤，老化，肌萎缩性侧索硬化症（ALS），弗里德里希共济失调，巴特尔病，阿尔茨海默病，视神经炎，莱伯氏遗传性视神经病变（LHON），自闭症，Rett综合征，Batten病，Angelman综合征，Leigh病，Fragile-X综合征， 抑郁症，帕金森病，线粒体疾病，发育障碍，代谢疾病疾病和/或自身免疫性疾病，通过用DNP治疗诱导内源性BDNF表达以保护神经肌肉功能障碍/ d 异常和/或神经变性和/或肌肉消瘦。 每天在一定剂量范围内对小鼠施用DNP，随后BDNF在脑中的表达显示剂量依赖性和非线性表达增加。

公开(公告)号：US20230100940A1

公开(公告)日：2023-03-30

申请号：US17840436

申请日：2022-06-14

申请人： MITOCHON PHARMACEUTICALS, INC. ,  BIOVENTURES, LLC

发明人： John Gerard Geisler ,  Robert Alonso ,  Peter Anthony Crooks ,  Narsimha Reddy Penthala ,  Zaineb Albayati

IPC分类号： A61K31/5375 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/06 ,  A61K31/4409 ,  C07C323/58 ,  C07F9/12 ,  A61K31/40 ,  A61K31/265 ,  A61K31/27 ,  C07C205/37 ,  A61K31/223 ,  A61K31/4406 ,  A61K31/661 ,  C07F9/09 ,  A61K31/221 ,  C07C271/44 ,  C07C219/04 ,  C07C271/52 ,  C07C229/26 ,  A61K31/44 ,  A61K31/4402 ,  C07C229/08 ,  C07C229/22

摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

公开(公告)号：US11406642B2

公开(公告)日：2022-08-09

申请号：US16695653

申请日：2019-11-26

申请人： MITOCHON PHARMACEUTICALS, INC. ,  BIOVENTURES, LLC

发明人： John Gerard Geisler ,  Robert Alonso ,  Peter Anthony Crooks ,  Narsimha Reddy Penthala ,  Zaineb Albayati

IPC分类号： A61K31/5375 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/06 ,  A61K31/4409 ,  C07C323/58 ,  C07F9/12 ,  A61K31/40 ,  A61K31/265 ,  A61K31/27 ,  C07C205/37 ,  A61K31/223 ,  A61K31/4406 ,  A61K31/661 ,  C07F9/09 ,  A61K31/221 ,  C07C271/44 ,  C07C219/04 ,  C07C271/52 ,  C07C229/26 ,  A61K31/44 ,  A61K31/4402 ,  C07C229/08 ,  C07C229/22 ,  C07D295/145 ,  C07D295/088 ,  C07D295/205 ,  C07D213/40 ,  C07D295/13

摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

公开(公告)号：US20200093831A1

公开(公告)日：2020-03-26

申请号：US16695653

申请日：2019-11-26

申请人： MITOCHON PHARMACEUTICALS, INC. ,  BIOVENTURES, LLC

发明人： John Gerard Geisler ,  Robert Alonso ,  Peter Anthony Crooks ,  Narsimha Reddy Penthala ,  Zaineb Albayati

IPC分类号： A61K31/5375 ,  C07C229/22 ,  C07C229/08 ,  A61K31/4402 ,  A61K31/44 ,  C07C229/26 ,  C07C271/52 ,  C07C219/04 ,  C07C271/44 ,  A61K31/221 ,  C07F9/09 ,  A61K31/661 ,  A61K31/4406 ,  A61K31/223 ,  C07C205/37 ,  A61K31/27 ,  A61K31/265 ,  A61K31/40 ,  C07F9/12 ,  C07C323/58 ,  A61K31/4409 ,  A61K31/06 ,  A61K31/495 ,  A61K31/4453

摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

公开(公告)号：US10220006B2

公开(公告)日：2019-03-05

申请号：US15707239

申请日：2017-09-18

申请人： Mitochon Pharmaceuticals, Inc.

发明人： Robert Alonso ,  John Gerard Geisler

IPC分类号： A61K31/045 ,  A61K31/06 ,  A61K9/00

摘要： A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GB S), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. DNP was administered to mice daily over a range of doses, and subsequently BDNF expression in the brain showed a dose dependent and non-linear increase in expression.

公开(公告)号：US09763896B2

公开(公告)日：2017-09-19

申请号：US15002531

申请日：2016-01-21

申请人： Mitochon Pharmaceuticals LLC

发明人： Robert Alonso ,  John Gerard Geisler

IPC分类号： A61K31/045 ,  A61K31/06 ,  A61K9/00

CPC分类号： A61K31/06 ,  A61K9/0019 ,  A61K9/0053

摘要： A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. DNP was administered to mice daily over a range of doses, and subsequently BDNF expression in the brain showed a dose dependent and non-linear increase in expression.

公开(公告)号：US11717497B2

公开(公告)日：2023-08-08

申请号：US17093193

申请日：2020-11-09

申请人： Mitochon Pharmaceuticals, Inc.

发明人： Robert Alonso ,  John Gerard Geisler

IPC分类号： A61K31/06 ,  A61K9/00

CPC分类号： A61K31/06 ,  A61K9/0019 ,  A61K9/0053

摘要： A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeneration and/or muscle wasting. DNP was administered to mice daily over a range of doses, and subsequently BDNF expression in the brain showed a dose dependent and non-linear increase in expression.

公开(公告)号：US10548900B2

公开(公告)日：2020-02-04

申请号：US15451938

申请日：2017-03-07

申请人： Mitochon Pharmaceuticals, INC. ,  Bioventures, LLC

发明人： John Gerard Geisler ,  Robert Alonso ,  Peter Anthony Crooks ,  Narsimha Reddy Penthala ,  Zaineb Albayati

IPC分类号： A61K31/535 ,  A61K31/5375 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/06 ,  A61K31/221 ,  A61K31/223 ,  A61K31/265 ,  A61K31/27 ,  A61K31/40 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/661

摘要： A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.